![]() Legend Biotech Legend Biotech is a biopharmaceutical company engaged in the discovery and development of cell therapies for oncology and other indications.
| ![]() NovoCure NovoCure is a company engaged in the development, manufacture, and commercialization of solutions for the treatment of solid tumors. | ![]() Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. | ![]() Innovent Biologics Innovent Biologics is a biopharmaceutical company developing and manufacturing monoclonal antibodies. | ![]() Autolus Autolus Therapeutics is a private biopharmaceutical company, focused on the development and commercialization of engineered T-cell immunotherapy products. | ![]() Allogene Therapeutics Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer. | |
Founding Date | Founding Date 2014 | Founding Date 2000 | Founding Date 1996 | Founding Date 2011 | Founding Date 2014 | Founding Date 2018 |
Type | Type Public | Type Public | Type Public | Type Private | Type Public | Type Public |
Tags | ||||||
Locations | Locations Somerset, US HQ Ghent, BE Nanjing, CN Hong Kong, HK Dublin, IE Piscataway, US | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations Fangshan Qu, CN HQ | Locations London, GB HQ London, GB | Locations South San Francisco, US HQ | |
Employees | Employees 2,90012% increase | Employees 1,488 | Employees 75,883 | Employees 831 | Employees 647 | Employees 2263% decrease |
Valuation ($) | Valuation ($) 8.4 b | Valuation ($) 1.8 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 1.2 b | Valuation ($) 585.5 m |
Financial | ||||||
Revenue (est.) | Revenue (est.) $1b (FY, 2025) | Revenue (est.) $655.4m (FY, 2025) | Revenue (est.) $56.7b (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $75.4m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods $408.1m (FY, 2025) | Cost of goods $166.9m (FY, 2025) | Cost of goods $8.4b (FY, 2025) | Cost of goods N/A | Cost of goods $86.6m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit $620.8m (FY, 2025) | Gross profit $488.5m (FY, 2025) | Gross profit $49.8b (FY, 2025) | Gross profit N/A | Gross profit ($10.7m) (FY, 2025) | Gross profit N/A |
Net income | Net income ($296.8m) (FY, 2025) | Net income ($136.2m) (FY, 2025) | Net income $14b (FY, 2025) | Net income N/A | Net income ($287.5m) (FY, 2025) | Net income ($190.9m) (FY, 2025) |
Operating ⚠ | ||||||
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 3 (FY, 2021) | Phase III Trials Products 44 (FY, 2022) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A |
Funding | ||||||
Total funding raised | Total funding raised $ 150.5m | Total funding raised N/A | Total funding raised $ 6.5m | Total funding raised $ 560m | Total funding raised $ 281.7m | Total funding raised $ 532m |

NovoCure is a company engaged in the development, manufacture, and commercialization of solutions for the treatment of solid tumors.
View company
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
View company
Innovent Biologics is a biopharmaceutical company developing and manufacturing monoclonal antibodies.
View company
Autolus Therapeutics is a private biopharmaceutical company, focused on the development and commercialization of engineered T-cell immunotherapy products.
View company